IDH1 and acute myeloid leukemia: With the advent of novel highly active agents, especially venetoclax [42,46,47], glasdegib [48] and IDH1/2 inhibitors [49,50], the role of chemotherapy as a frontline treatment of elderly and unfit AML patients is questioned [51].